May 31, 2026 · Science & Research Daily Digest
Science, space, biopharma, and climate research highlights for May 31, 2026, with summaries, links, and commentary.
I. Space & Deep Space
1. NASA confirms natural meteor breakup over New England; ~300 tons TNT equivalent sonic boom
Summary:
Per The Verge and Phys.org (May 31, 2026), at roughly 2:06 p.m. ET on Saturday, May 31, a natural meteor about 0.9 m (~3 ft) wide entered the atmosphere at ~120,700 km/h (~75,000 mph) and fragmented near 64 km (40 miles) altitude over northeastern Massachusetts and southeastern New Hampshire. NASA estimates energy release equivalent to ~300 tons of TNT, producing a widely heard double sonic boom and building shaking across New England; GOES-19 also captured the fireball. USGS and NASA ruled out earthquakes and satellite/debris re-entry; the event was not tied to an active meteor shower. The American Meteor Society received reports from Delaware to Montreal.
Links:
- The Verge — NASA confirms exploding meteor caused the sonic boom over Boston
- Phys.org — Meteor over Massachusetts causes explosion reports, sightings from Delaware to Montreal
Commentary:
Sub-meter bodies exploding at altitude can masquerade as regional “pseudo-earthquakes,” underscoring the need to separate seismological events from atmospheric shock waves in public alerting.
2. “Phoebe”: lunar-mass microlensing candidate in the Milky Way halo may be a primordial black hole
Summary:
Per ScienceAlert and Phys.org (around May 31, 2026), Swinburne University–led researchers re-analyzed a ~1-hour microlensing brightening of an LMC star recorded on Dec. 18, 2019, by DECam high-cadence observations, nicknaming the lens “Phoebe.” The arXiv preprint (AMPM II) infers a mass of ~3 lunar masses at ~59,630 light-years, with membership in the Milky Way dark-matter halo favored over known stellar populations by ~five orders of magnitude; after excluding instrumental glitches and stellar variability, a primordial black hole (PBH) is the preferred interpretation among alternatives including halo rogue planets. The work is not yet peer-reviewed and intersects ongoing debate over Andromeda microlensing candidates reported in early 2026.
Links:
- arXiv — AMPM II: A Lunar-Mass Primordial Black Hole Microlensing Candidate in the Milky Way Halo
- ScienceAlert — Strange Event Might Have Been A Primordial Black Hole Winking At Us
Commentary:
High-cadence follow-up from Roman or Vera C. Rubin could turn lunar-mass PBHs into rare probes of dark-matter composition and early-universe inflation physics.
3. After New Glenn static-fire explosion, Artemis lunar landing timelines face pressure
Summary:
Per The Verge, Time, and follow-up coverage (May 29–31, 2026), Blue Origin’s ~98 m New Glenn rocket exploded during a May 28 static fire at Cape Canaveral LC-36, heavily damaging the vehicle and pad infrastructure (transporter-erector, lightning towers) with no injuries. NASA Administrator Jared Isaacman pledged joint investigation and assessment of impacts on Artemis and Moon Base goals; analysts note Blue Origin has only this pad for New Glenn, with repairs potentially taking many months, putting fall 2026 Blue Moon cargo plans and 2027 Artemis III–linked contracts at risk and increasing near-term reliance on SpaceX Starship for lunar landing capacity.
Links:
- The Verge — Blue Origin explosion is a major setback for NASA’s Moon plans
- Time — The Impact of Blue Origin's Rocket Explosion on NASA's Lunar Goals
Commentary:
A second major New Glenn setback within six weeks of the NG-3 upper-stage anomaly concentrates “single-pad” risk for U.S. commercial heavy lift and lunar logistics.
II. Biomedicine & Health
4. RASolute 302 in NEJM and ASCO plenary: daraxonrasib median OS 13.2 vs 6.7 months in second-line metastatic pancreatic cancer
Summary:
Per Dana-Farber, Revolution Medicines, and Science News (May 31, 2026), global randomized open-label Phase 3 RASolute 302 (NCT06625320) results were presented at ASCO (LBA5) by Brian Wolpin and published simultaneously in the New England Journal of Medicine. Among 500 previously treated metastatic pancreatic ductal adenocarcinoma patients (91.8% RAS G12), oral RAS(ON) multiselective inhibitor daraxonrasib vs investigator-choice chemotherapy yielded median overall survival 13.2 vs 6.7 months (HR=0.40, P<0.001) and median PFS 7.2 vs 3.6 months; treatment-related discontinuation 1.2% vs 11.2%. FDA expanded access was authorized May 1; the sponsor cites planned expedited review.
Links:
- NEJM — Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
- Dana-Farber — RAS(ON) Inhibitor Doubles Median Overall Survival in Phase 3 Trial
Commentary:
With >90% of PDAC driven by RAS yet long “undruggable,” the first Phase 3 win over chemotherapy in second line could reset standards and force earlier-line and surgical-window trials.
5. Akeso ivonescimab (PD-1/VEGF bispecific) HARMONi-6: first-line sq-NSCLC OS HR=0.66; Lancet + ASCO plenary
Summary:
Per Akeso and media reports (May 31, 2026), Phase 3 HARMONi-6/AK112-306 results were released at ASCO plenary and published in The Lancet: 532 advanced squamous NSCLC patients received ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy. At median follow-up ~21.36 months (data cut Feb. 27, 2026), death risk fell 34% (HR=0.66, 95% CI 0.50–0.87, P=0.0017) with median OS 27.9 vs 23.7 months; prespecified PFS median 11.1 vs 6.9 months (HR=0.60). Sponsors describe this as the first Phase 3 in lung cancer to beat PD-1+chemo on both OS and PFS and to fill an anti-angiogenesis gap in first-line sq-NSCLC.
Links:
- Sina Finance — HARMONi-6 OS benefit (HR=0.66)
- Futunn — Statistically significant OS improvement, HR=0.66
Commentary:
A PD-1/VEGF bispecific beating PD-1+chemo in first line supplies top-tier evidence for dual-pathway immuno-oncology rather than “PD-1 stacking alone.”
6. Dizal sunvozertinib WU-KONG28: NEJM + ASCO LBA show first-line PFS win in EGFR exon20ins NSCLC
Summary:
Per company and media reports (May 31, 2026), multinational Phase 3 WU-KONG28 was presented as an ASCO LBA and published in NEJM: 324 treatment-naïve EGFR exon20 insertion NSCLC patients were randomized 1:1 to sunvozertinib 300 mg daily vs platinum doublet; blinded independent review showed statistically and clinically significant PFS improvement with consistent safety. The subtype accounts for ~10% of EGFR-mutant NSCLC; sunvozertinib is already approved in later lines in China and the U.S., and a first-line NDA is under NMPA priority review based on WU-KONG28.
Links:
Commentary:
A validated oral first-line monotherapy in exon20ins reshapes subtype stratification, guidelines, and reimbursement logic after years without a global Phase 3 benchmark.
7. Kelun-Biotech sac-TMT (TROP2 ADC) + pembrolizumab first-line NSCLC Phase 3 published in The Lancet
Summary:
Per Kelun-Biotech announcements (May 31, 2026), Phase 3 OptiTROP-Lung05 of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in PD-L1 TPS≥1%, EGFR/ALK-negative advanced NSCLC was published in The Lancet and presented at ASCO (abstract #8506). The company positions sac-TMT as the first marketed TROP2 ADC in lung cancer; a combination first-line indication NDA is under NMPA priority review. MSD is running 17 global Phase 3 sac-TMT programs.
Links:
- PRNewswire — OptiTROP-Lung05 Results Published in The Lancet
- Business News Taiwan — sac-TMT + pembrolizumab Lancet publication
Commentary:
A China-origin TROP2 ADC plus PD-1 first-line dataset in The Lancet signals parity with global ADC–IO evidence standards in lung cancer.
III. Climate & Environment
8. Communications Earth & Environment: Antarctic intermediate water ventilation spiked when AMOC weakened ~39,400 years ago
Summary:
Nadar et al. (Communications Earth & Environment, published May 24, 2026; DOI 10.1038/s43247-026-03659-w) reconstructed Antarctic Intermediate Water variability at ODP Site 1233 off Chile during Antarctic Isotope Maximum 8 (~37–39.4 ka). Around 39.4 ka, bottom waters warmed, oxygen rose sharply, and carbon isotopes increased—signaling stronger ventilation and nutrient redistribution consistent with modeled AMOC weakening, thermocline deepening, and remote Southern Ocean response. Authors warn that if today’s AMOC slowdown continues, similar levers could shift oxygen, carbon, and nutrients globally and test CO₂ rise hypotheses tied to past Atlantic slowdowns.
Links:
- Communications Earth & Environment — Rapid increase in Antarctic intermediate water ventilation related to past AMOC weakening
- Earth.com — A deep ocean change near Antarctica may follow Atlantic slowdowns
Commentary:
Sediments turn the modeled North Atlantic–Southern Ocean coupling into a detectable, rapid paleo fact—an anchor for assessing modern AMOC decline.
9. Nature Communications: anthropogenic warming advances global flood timing by ~0.43 days per 0.5°C
Summary:
Qi et al. (Nature Communications, published May 29, 2026; DOI 10.1038/s41467-026-73839-x) used multi-model ensembles for 1.5°C–4.0°C warming. Global flood timing advances ~0.43±0.25 days per 0.5°C anthropogenic warming, with regional divergence (early-flood regions earlier, late-flood regions later). At 1.5°C, ~50.73±4.23% of global land sees flood-timing shifts >7 days, rising to ~52.85±3.20% at 2.0°C; exposed populations are projected to grow in countries including China, India, and the United States. The authors urge treating timing alongside magnitude and frequency in adaptation planning.
Links:
Commentary:
Flood risk is not only “bigger and more often” but “sooner or later”—agriculture, urban drainage, and insurance must add a temporal dimension.
10. Nature: temporary CDR can physically offset methane, not long-lived CO₂
Summary:
He et al. (Nature, published May 27, 2026; DOI 10.1038/s41586-026-10607-3) propose a physics-based “two-basket” framework: because methane and temporary carbon storage both act on decadal-to-centennial climate, temporary CDR (e.g., ~20-year bioplastics, ~100-year durable wood) can compensate methane; neutralizing 1 kg CH₄ requires storing ~498 kg CO₂ for 20 years or ~101 kg for 100 years. Temporary CDR cannot fully offset centennial CO₂; continuous agricultural methane needs continuously matched CDR, with safeguards against reversal and moral hazard.
Links:
- Nature — Temporary carbon dioxide removal to offset short-lived climate forcers
- Phys.org — Temporary carbon removal could help support climate goals, if used correctly
Commentary:
The study draws scientific boundaries for livestock-heavy economies while closing loopholes that would use short-lived storage credits against fossil CO₂.
IV. Fundamental Research
11. Persistent LHCb B-meson anomalies: Scientific American on possible Z′ or leptoquark new physics
Summary:
Per Scientific American (May 31, 2026), CERN’s LHCb experiment continues to show deviations in B-meson decay patterns vs Standard Model expectations; related analyses are accepted at Physical Review Letters. Theorists suggest virtual Z′ bosons (new force, flavor-dependent couplings) or leptoquarks could explain bottom-to-strange transitions and decay angles; significance is on the order of four sigma—among the few remaining beyond–Standard Model hints in flavor physics pending more data and channels.
Links:
Commentary:
With few direct new particles at the LHC energy frontier, precision flavor measurements remain a sensitive indirect window to TeV-scale physics.
12. Cortical Labs trains ~200,000 human neurons on CL1 chip to play Doom
Summary:
Per Phys.org and AFP/Straits Times (May 31, 2026), Melbourne-based Cortical Labs cultured ~200,000 human neurons from blood-derived stem cells on a multi-electrode CL1 chip, encoding Doom’s 3D environment as electrical stimulation; closed-loop feedback yielded adaptive navigation, aiming, and firing within about a week. The firm launched a commercial “biological computer” in March 2025 after earlier Pong demos; cells live ~six months, outputs remain unstable and not fully programmable, but the team cites far lower energy than comparable silicon workloads and drug-screening use cases.
Links:
- Phys.org — Researchers teach brain cells to play 'Doom'
- The Straits Times — Australian researchers teach brain cells to play ‘Doom’
Commentary:
Moving from 2D Pong to 3D FPS is a complexity jump for biological closed-loop learning; reproducibility and ethics will decide whether this leaves demo stage.
13. NSF reportedly slows new awards to Duke, Harvard, Princeton, Yale
Summary:
Per Scientific American (May 31, 2026, citing Nature’s news team), NSF’s Office of Award Management allegedly flagged “Future Awards to Organization on Hold” on April 9, 2026, for Duke, Harvard, Princeton, and Yale, slowing dozens of new grants—~85% in math, physical sciences, and engineering, including quantum information projects. On May 28 the hold note was removed for some schools and a few Harvard/Duke awards released; NSF’s fiscal year also faces delays from a late-2025 shutdown and budget timing.
Links:
Commentary:
Linking basic-research funding to institutional politics risks idle talent and facilities in fields labeled national priorities such as quantum science.
Today's Summary
- Space and astronomy: a New England fireball and the “Phoebe” microlensing candidate share the day—near-Earth public safety signals vs. dark-matter/PBH frontiers—while Blue Origin’s explosion keeps squeezing Artemis commercial landing schedules.
- Oncology: ASCO Sunday delivered daraxonrasib pancreatic Phase 3/NEJM alongside ivonescimab sq-NSCLC, sunvozertinib exon20ins, and sac-TMT TROP2 ADC data—a “RAS + immuno-combo + ADC” wave from China and U.S. innovators.
- Climate science: AMOC–Antarctic intermediate water coupling, advancing global flood timing, and temporary CDR matched to methane all stress temporal structure in Earth-system response and policy accounting.
- Frontiers: LHCb flavor anomalies, neurons playing Doom, and NSF grant holds touch new physics, neuro–silicon hybrids, and research governance.
Daily Framing:
Today sits at the intersection of sky events and primordial-black-hole candidates, pancreatic RAS drugs and ASCO China readouts, ocean circulation–flood timing–methane compensation frameworks, and particle anomalies plus biological computers—all competing for the same policy and investment attention.
This digest is compiled from live web search and is for reference only; facts are subject to original sources.
Date: May 31, 2026 (Sunday)